Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/ijms22052433 http://scihub22266oqcxt.onion/10.3390/ijms22052433 33670942!7957700!33670942     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Mol+Sci 2021 ; 22 (5): ä Nephropedia Template TP {{tp|p=33670942|t=2021. Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer |pdf=|usr=}}{{33670942}} gab.com Text Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer JO: Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=33670942 #FOAvip Immunotherapy is a highly emerging form of breast cancer therapy that enables clinicians to target cancers with specific receptor expression profiles. Two popular immunotherapeutic approaches involve chimeric antigen receptor-T cells (CAR-T) and bispecific antibodies (BsAb). Briefly mentioned in this review as well is the mRNA vaccine technology recently popularized by the COVID-19 vaccine. These forms of immunotherapy can highly select for the tumor target of interest to generate specific tumor lysis. Along with improvements in CAR-T, bispecific antibody engineering, and therapeutic administration, much research has been done on novel molecular targets that can especially be useful for triple-negative breast cancer (TNBC) immunotherapy. Combining emerging immunotherapeutics with tumor marker discovery sets the stage for highly targeted immunotherapy to be the future of cancer treatments. This review highlights the principles of CAR-T and BsAb therapy, improvements in CAR and BsAb engineering, and recently identified human breast cancer markers in the context of in vitro or in vivo CAR-T or BsAb treatment. Twit Text FOAVip Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer ????Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=33670942 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33670942 #FOAvip English Wikipedia <ref>{{Cite pmid|33670942}}</ref> Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer #MMPMID33670942 Sivaganesh V; Promi N; Maher S; Peethambaran B Int J Mol Sci 2021[Feb]; 22 (5): ä PMID33670942show ga Immunotherapy is a highly emerging form of breast cancer therapy that enables clinicians to target cancers with specific receptor expression profiles. Two popular immunotherapeutic approaches involve chimeric antigen receptor-T cells (CAR-T) and bispecific antibodies (BsAb). Briefly mentioned in this review as well is the mRNA vaccine technology recently popularized by the COVID-19 vaccine. These forms of immunotherapy can highly select for the tumor target of interest to generate specific tumor lysis. Along with improvements in CAR-T, bispecific antibody engineering, and therapeutic administration, much research has been done on novel molecular targets that can especially be useful for triple-negative breast cancer (TNBC) immunotherapy. Combining emerging immunotherapeutics with tumor marker discovery sets the stage for highly targeted immunotherapy to be the future of cancer treatments. This review highlights the principles of CAR-T and BsAb therapy, improvements in CAR and BsAb engineering, and recently identified human breast cancer markers in the context of in vitro or in vivo CAR-T or BsAb treatment. |Animals[MESH] |Antibodies, Bispecific/immunology/therapeutic use[MESH] |Biomarkers, Tumor[MESH] |Breast Neoplasms/immunology/*therapy[MESH] |CD8-Positive T-Lymphocytes/immunology[MESH] |COVID-19 Vaccines/immunology[MESH] |COVID-19/immunology[MESH] |Cancer Vaccines/administration & dosage/immunology[MESH] |Female[MESH] |Humans[MESH] |Immunotherapy, Adoptive/methods[MESH] |Immunotherapy/*methods[MESH] |Molecular Targeted Therapy[MESH] |Receptors, Chimeric Antigen/immunology[MESH] |SARS-CoV-2/immunology[MESH] |Triple Negative Breast Neoplasms/immunology/therapy[MESH] |Vaccines, Synthetic/administration & dosage/immunology[MESH]Emerging Immunotherapies against Novel Molecular Targets in Breast Can(epmc).pdf DeepDyve Pubget Overpricing